Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group

Next-Generation Sequencing is needed for the accurate genetic risk stratification of acute myeloid leukemia according to European LeukemiaNet (ELN) guidelines. We validated and compared the 2022 ELN risk classification in a real-life cohort of 546 intensively and 379 non-intensively treated patients...

Descripción completa

Detalles Bibliográficos
Autores: Sargas, Claudia, Ayala, Rosa, Larrayoz, Maria J, Chillon, Maria C, Rodriguez-Arboli, Eduardo, Bilbao, Cristina, Prados de la Torre, Esther, Martinez-Cuadron, David, Rodriguez-Veiga, Rebeca, Boluda, Blanca, Gil, Cristina, Bernal, Teresa, Bergua, Juan, Algarra, Lorenzo, Tormo, Mar, Martinez-Sanchez, Pilar, Soria, Elena, Serrano, Josefina, Alonso-Dominguez, Juan M, Garcia, Raimundo, Amigo, Maria Luz, Herrera-Puente, Pilar, Sayas, Maria J, Lavilla-Rubira, Esperanza, Martinez-Lopez, Joaquin, Calasanz, Maria J, Garcia-Sanz, Ramon, Perez-Simon, Jose A, Gomez Casares, Maria T, Sanchez-Garcia, Joaquin, Barragan, Eva, Montesinos, Pau
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Institución:INCLIVA
Repositorio:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
OAI Identifier:oai:incliva.fundanetsuite.com:p17454
Acceso en línea:https://incliva.portalinvestigacion.com/publicaciones/17454
Access Level:acceso abierto
Descripción
Sumario:Next-Generation Sequencing is needed for the accurate genetic risk stratification of acute myeloid leukemia according to European LeukemiaNet (ELN) guidelines. We validated and compared the 2022 ELN risk classification in a real-life cohort of 546 intensively and 379 non-intensively treated patients. Among fit patients, those aged >= 65 years old showed worse OS than younger regardless risk classification. Compared with the 2017 classification, 14.5% of fit patients changed the risk with the 2022 classification, increasing the high-risk group from 44.3% to 51.8%. 3.7% and 0.9% FLT3-ITD mutated patients were removed from the favorable and adverse 2017 categories respectively to 2022 intermediate risk group. We suggest that midostaurin therapy could be a predictor for 3 years OS (85.2% with vs. 54.8% without midostaurin, P = 0.04). Forty-seven (8.6%) patients from the 2017 intermediate group were assigned to the 2022 adverse-risk group as they harbored myelodysplasia (MDS)-related mutations. Patients with one MDS-related mutation did not reach median OS, while patients with >= 2 mutations had 13.6 months median OS (P = 0.002). Patients with TP53 +/- complex karyotype or inv(3) had a dismal prognosis (7.1 months median OS). We validate the prognostic utility of the 2022 ELN classification in a real-life setting providing supportive evidences to improve risk stratification guidelines.

Similares en LA Referencia